Agreement offers new HIV prevention possibilities for women
The International Partnership for Microbicides (IPM) announced that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland.
The agreement expands on IPM’s existing rights to develop, manufacture and commercialize dapivirine-based products for use by women in developing countries such as a vaginal ring that combines dapivirine and a contraceptive.
This marks a proud moment for Irish Aid, a key supporter of IPM since its founding in 2002 in their goal of accelerating the development of – and access to – effective microbicides for women living in the world’s poorest settings. Congratulations also to Janssen R&D Ireland for their insight and innovation!
“This agreement could have profound implications for women’s health,” said Dr. Peter Piot, director of the London School of Hygiene & Tropical Medicine and founding executive director of UNAIDS. “Not only will it expand women’s access to affordable, potentially lifesaving prevention products but also make sure research into new tools continues. It serves as a valuable model for how creative partnerships can help tackle some of the most daunting global health challenges.”
The importance of such partnerships cannot be underestimated. Public-private partnerships are fast becoming a cornerstone for tackling global health issues. And the issue of HIV which is being targeted by Janssen and IPM is a very real one. Despite the fall in HIV infection rates by a third since 2001, there are still too many women yet to benefit from treatment breakthroughs. Indeed, in some parts of sub-Saharan Africa, women aged 15 – 24 are three to four times more likely to be infected with HIV as their male counterparts.
Currently IPM has rights to develop, manufacture and commercialise dapivirine-based products for women in developing countries. This new agreement with Janssen will provide women in developed countries with access to similar dapivirine products. This new market will then help to fund IPM’s nonprofit mission amongst those women most affected by HIV – by developing HIV and multipurpose prevention technologies (MPTs) for women – in resource-poor countries.
The partnership of Janssen and IPM has gone a long way in bringing ARV access to those most in need, with Janssen licensing dapivirine to IPM under a royalty-free agreement in 2004 to develop the ARV medicine as a microbicide specifically for women in developing countries. Janssen’s newly-established Global Public Health group marks the next step in their longstanding collaboration with IPM – one which has potential to secure womens’ futures, and access to prevention products, worldwide.
“Our worldwide rights agreement with Janssen is a powerful example of how public-private partnerships can accelerate access to urgently needed, affordable health products,” added Dr. Rosenberg. “By pooling the expertise of partners across sectors, we can more effectively help women at risk for HIV and, ultimately, end the spread of HIV/AIDS altogether.”
- 4th Global Forum on HRH
- Access to Medicines
- Archive Page Weekly COVID Webinars
- Clean Cooking 2019
- Climate Change and Health Conference 2017
- Conference Abstracts
- Conference Materials
- Covid FAQ
- Dashboard and online resources
- ESTHER Alliance
- Events & News
- Global Health Exchange 2018
- Global Health Exchange 2019
- Global Health symposium 2019
- Health Workforce/HRH
- Homepage Featured
- Homepage recent posts
- IFGH 2011-2012 Conference and Events
- IFGH 2014 Conference
- IFGH Multimedia
- Irish AIDS Day 2017
- Irish News and Feeds
- Key Correspondent Articles
- Key Correspondent News
- Maternal Health
- News & Events
- Our LMIC's Resources for COVID19
- Partner Country News and Feeds
- Past Events
- Recurring events
- Reports & Publications
- Student Outreach Group
- Students Corner
- Upcoming Events